Omixon specializes in the analysis of targeted Next Generation Sequencing (NGS) data. Using our Target application suite we offer high resolution HLA typing. We also help scientists and clinicians to investigate challenging genomic regions such as breast cancer susceptibility genes (BRCA1 and BRCA2), cystic fibrosis gene (CFTR), as well as custom panels.
Testimonials
Omixon Blog
Omixon is attending TCGC in San Francisco. Meet us there!
The Clinical Genome Conference (TCGC) 2013 brings together many constituencies for frank and vital discussion of the applications, questions and solutions surrounding clinical genome analysis, including scientists, physicians, diagnosticians, genetic counselors, bioinformaticists, ethicists, regulators, insurers, lawyers, and administrators.
Omixon is exhibiting at TCGC in San Francisco, from 25th to 28th June, 2013.
Our CTO, Tim Hague and Hajnalka Hejja will be there.
By
Hajnalka Hejja, MD
0 comments
The Omixon App in Illumina’s genomics cloud computing and storage platform
It’s a huge pleasure to announce that BaseSpace, Illumina’s genomics cloud computing and storage platform, just became commercially available and one of the first apps was launched by Omixon. The commercial release includes a fully supported BaseSpace Apps store for quick and easy access to Illumina and third-party bioinformatics applications.
By
Hajnalka Hejja, MD
0 comments
